NutraRX Digest-Able
- Manufacturer
- Feelgood Health | W. Last
- Effective date
- 2010-09-23
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:38
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
Reduces digestive upset and strengthens the entire gastrointestinal tract
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy for the temporary relief of common stomach ailments such as indigestion and discomfort. Also promotes digestive health.
DOSAGE & ADMINISTRATION SECTION
Directions: Acute: Chew 2-4 tablets every 60 minutes until symptoms subside (up to 10 doses). Thereafter chew 2-4 tablets three times daily.
GENERAL PRECAUTIONS SECTION
Warning: If symptoms persist or worsen, a health care professional should be consulted.Keep this and all medicines from the reach of children.
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of biochemic tissue salts: Kali phos (6X) (HPUS), Nat phos (6X) (HPUS), Calc phos (6X) (HPUS)
INACTIVE INGREDIENT SECTION
Lactose (inactive ingredient).
PREGNANCY SECTION
If pregnant or breastfeeding, ask a health professional before use.
WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives. Safe for all ages and during pregnancy.
INFORMATION FOR PATIENTS SECTION
All NutraRx products are especially formulated by experts in the field of natural health and are manufactured according to the highest pharmaceutical standards for maximum safety and effectiveness.
NutraRx
6531 Park of Commerce
Blvd., Suite 160
Boca Raton, FL 33487
Phone: +1.877.289.1235
International: +1.561.999.8857
Made in South Africa
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States (HPUS).
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medicines from the reach of children.
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68647-194-10 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-bfe2-621f-e053-dbdaa90a74ad | NUTRARX DIGEST-ABLE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-194-10 | NutraRX Digest-Able | 125 in 1 BOTTLE, GLASS | TABLET | 125 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POTASSIUM PHOSPHATE, DIBASIC | ACTIVE INGREDIENT | CI71S98N1Z | 1 | |
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | ACTIVE INGREDIENT | 22ADO53M6F | 1 | |
| TRIBASIC CALCIUM PHOSPHATE | ACTIVE INGREDIENT | 91D9GV0Z28 | 1 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 1 | |
| POTASSIUM CATION | ACTIVE MOIETY | 295O53K152 | 1 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Products#
Every source-derived product name is available through these pages.
- NutraRX Digest-Able
- Kali phos, Nat phos, Calc phos
- POTASSIUM PHOSPHATE, DIBASIC
- POTASSIUM CATION
- SODIUM PHOSPHATE, DIBASIC ANHYDROUS
- SODIUM CATION
- TRIBASIC CALCIUM PHOSPHATE
- CALCIUM CATION
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-194 | 68647-194-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POTASSIUM PHOSPHATE, DIBASIC | CI71S98N1Z | ACTIB |
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | 22ADO53M6F | ACTIB |
| TRIBASIC CALCIUM PHOSPHATE | 91D9GV0Z28 | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 82f591bb-ef54-456f-bfcf-cec88942b079 | a7ecb597-7356-4a17-8348-d76b92c3beb5 | 2010-09-23 | Warnings | 82f591bb-ef54-456f-bfcf-cec88942b079 a7ecb597-7356-4a17-8348-d76b92c3beb5 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
